☆ 4.7 Article

The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials

CRITICAL CARE (2023)

Related references

Note: Only part of the references are listed.

Article Critical Care Medicine

A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19

Michael E. Bowdish et al.

Summary: This study evaluated the efficacy and safety of allogeneic mesenchymal cells in patients with moderate and/or severe COVID-19-related acute respiratory distress syndrome. The results showed that cell therapy did not significantly improve 30-day survival or 60-day ventilator-free days compared to the control group. However, cell therapy did not cause significant adverse events.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial

Lei Shi et al.

Summary: The study found that UC-MSC treatment has a positive effect on the long-term recovery of COVID-19 patients, improving lung lesions and reducing symptoms. Compared to the placebo group, more patients in the MSC group had normal CT images at 12 months.

EBIOMEDICINE (2022)

Add to Collection

Article Medicine, Research & Experimental

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo- controlled phase 2 trial

Ellen Gorman et al.

Summary: This study aims to evaluate the safety and efficacy of a novel umbilical cord-derived mesenchymal stromal cell product (REALIST ORBCEL-C) in patients with ARDS due to COVID-19 and other causes. The trial consists of two phases: a dose-escalation pilot trial and a randomized, placebo-controlled trial. The primary outcomes include the incidence of serious adverse events and oxygenation index at day 7. The study will be reported according to the CONSORT 2010 statement.

TRIALS (2022)

Add to Collection

Article Cell & Tissue Engineering

Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial

Carmen Lucia Kuniyoshi Rebelatto et al.

Summary: COVID-19 is a multisystem disease with acute and persistent symptoms. Using umbilical cord MSCs as adjunctive therapy is safe and can prevent severe complications in the early stage, as well as reducing postacute sequelae in the chronic phase.

STEM CELL RESEARCH & THERAPY (2022)

Add to Collection

Article Cell & Tissue Engineering

Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial

Najmeh Kaffash Farkhad et al.

Summary: This study demonstrates that multiple intravenous transplantations of allogenic UC-MSCs are a safe procedure for non-severe COVID-19-induced ARDS patients, and it has the potential to reduce cytokine storm and improve respiratory functions.

STEM CELL RESEARCH & THERAPY (2022)

Add to Collection

Article Cell & Tissue Engineering

Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment

Hamid Reza Aghayan et al.

Summary: This study aimed to evaluate the safety of intravenous injection of placenta-derived mesenchymal stem cells (PL-MSCs) in patients with COVID-19-induced acute respiratory distress syndrome (ARDS). The results demonstrated that the administration of PL-MSCs was safe and feasible, with no adverse events observed. There were no significant differences in clinical and laboratory parameters between the treatment and control groups. Further studies are needed to evaluate the efficacy of this treatment modality using higher cell doses and repeated injections.

STEM CELL RESEARCH & THERAPY (2022)

Add to Collection

Article Critical Care Medicine

Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial

Antoine Monsel et al.

Summary: The efficacy of UC-MSCs in patients with SARS-CoV-2-induced ARDS was assessed in this study. The results showed no significant difference in respiratory indicators between the UC-MSCs and placebo groups. The repeated UC-MSCs infusions did not lead to any serious adverse events during treatment or thereafter.

CRITICAL CARE (2022)

Add to Collection

Review Medicine, General & Internal

Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol

Aidan M. Kirkham et al.

Summary: This study aims to review ongoing and completed clinical research on the use of MSCs in treating COVID-19 to understand the potential benefits in different patient populations as evidence emerges. Repeated systematic searches and meta-analyses will be conducted to evaluate the efficacy of MSCs in treating COVID-19.

SYSTEMATIC REVIEWS (2021)

Add to Collection

Letter Medicine, Research & Experimental

Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial

Concepcion Payares-Herrera et al.

TRIALS (2021)

Add to Collection

Article Cell & Tissue Engineering

Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial

Giacomo Lanzoni et al.

Summary: The study confirmed safety of UC-MSC infusions in patients with COVID-19 ARDS. By reducing inflammatory cytokines, significant improvement was observed in UC-MSC-treated patients on day 6. The treatment markedly increased patient survival rate, SAE-free survival, and time to recovery.

STEM CELLS TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update

Waleed Alhazzani et al.

Summary: The Surviving Sepsis Campaign Coronavirus Disease 2019 panel issued nine statements on managing severe or critical coronavirus disease 2019 in the ICU, including recommendations for systemic corticosteroids and venous thromboprophylaxis while strongly advising against the use of hydroxychloroquine. The panel also made suggestions for the use of dexamethasone, remdesivir, convalescent plasma, and therapeutic anticoagulation, based on the available evidence.

CRITICAL CARE MEDICINE (2021)

Add to Collection

Article Cell & Tissue Engineering

Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series

Seyed-Mohammad Reza Hashemian et al.

Summary: This study investigated the safety and effectiveness of multiple high-dose infusions of MSCs derived from placenta and umbilical cord in critically ill COVID-19-induced ARDS patients. Some patients showed significant improvement in respiratory distress and reduction in inflammatory markers after cell infusions.

STEM CELL RESEARCH & THERAPY (2021)

Add to Collection

Article Oncology

Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial

Xiaowei Xu et al.

Summary: A study showed that using menstrual blood-derived MSCs to treat severe COVID-19 patients can reduce mortality, improve dyspnea, and increase oxygen saturation levels. This MSC-based therapy may be a promising alternative for treating severe COVID-19.

CLINICAL AND TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS

Katherine D. Wick et al.

Summary: The study shows that treatment with mesenchymal stromal cells significantly reduced lung injury biomarkers in ARDS patients. Airspace biomarkers provide additional value for studying the pathogenesis, treatment effects, and outcomes of ARDS.

JCI INSIGHT (2021)

Add to Collection

Article Cell & Tissue Engineering

Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial

Ismail Hadisoebroto Dilogo et al.

Summary: The use of umbilical cord mesenchymal stromal cells (UC-MSCs) as adjuvant treatment for critically ill patients with COVID-19 significantly increases the survival rate by modulating the immune system towards an anti-inflammatory state.

STEM CELLS TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Cell & Tissue Engineering

The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial

G. Adas et al.

Summary: The aim of the clinical trial was to control cytokine storm by administering MSCs to critically ill COVID-19 patients, evaluating healing effects, and systematically investigating treatment mechanisms. The results showed positive systematic and cellular effects of MSCs application in critically ill patients, playing an important role in curing and reducing mortality.

CELL TRANSPLANTATION (2021)

Add to Collection

Article Geriatrics & Gerontology

Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19

Martin Iglesias et al.

Summary: The study evaluated the safety of administering ahUCMSC for patients with severe ARDS caused by COVID-19 and observed a continuous increase in PaO2/FiO2 post-infusion, contributing to the survival of patients.

AGING AND DISEASE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial

Lei Shi et al.

Summary: This study demonstrates that treatment with human umbilical cord-mesenchymal stem cells (UC-MSCs) can significantly improve lung lesions in COVID-19 patients and potentially have therapeutic effects in the 6-minute walk test. The incidence of adverse events was similar in both groups, indicating the good safety profile of UC-MSCs treatment.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Dawei Wang et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Cell & Tissue Engineering

Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

Vikram Sengupta et al.

STEM CELLS AND DEVELOPMENT (2020)

Add to Collection

Article Cell & Tissue Engineering

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Lei Shu et al.

STEM CELL RESEARCH & THERAPY (2020)

Add to Collection

Article Cell & Tissue Engineering

Mesenchymal Stromal Cells Attenuate Infection-Induced Acute Respiratory Distress Syndrome in Animal Experiments: A Meta-Analysis

Wang Fengyun et al.

CELL TRANSPLANTATION (2020)

Add to Collection

Article Critical Care Medicine

Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study

Yiming Li et al.

CRITICAL CARE (2020)

Add to Collection

Article Respiratory System

The efficacy of mesenchymal stromal cell-derived therapies for acute respiratory distress syndrome-a meta-analysis of preclinical trials

Fengyun Wang et al.

RESPIRATORY RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Acute respiratory distress syndrome

Michael A. Matthay et al.

NATURE REVIEWS DISEASE PRIMERS (2019)

Add to Collection

Article Critical Care Medicine

Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury

Diana Islam et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)

Add to Collection

Article Critical Care Medicine

Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial

Michael A. Matthay et al.

LANCET RESPIRATORY MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

A. Combes et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Cell & Tissue Engineering

Combined Bone Marrow-Derived Mesenchymal Stromal Cell Therapy and One-Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial

Hugo Goulart de Oliveira et al.

STEM CELLS TRANSLATIONAL MEDICINE (2017)

Add to Collection

Review Critical Care Medicine

Is Acute Respiratory Distress Syndrome a Preventable Disease?

Hemang Yadav et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries

Giacomo Bellani et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

Add to Collection

Review Medicine, General & Internal

Acute respiratory distress syndrome

Rob Mac Sweeney et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Driving Pressure and Survival in the Acute Respiratory Distress Syndrome

Marcelo B. P. Amato et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Critical Care Medicine

Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial

Jennifer G. Wilson et al.

LANCET RESPIRATORY MEDICINE (2015)

Add to Collection

Article Respiratory System

Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

Guoping Zheng et al.

RESPIRATORY RESEARCH (2014)

Add to Collection

Article Critical Care Medicine

Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome

Kathleen D. Liu et al.

ANNALS OF INTENSIVE CARE (2014)

Add to Collection

Article Critical Care Medicine

A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD

Daniel J. Weiss et al.

CHEST (2013)

Add to Collection

Article Critical Care Medicine

Effects of Mesenchymal Stem Cell Therapy on the Time Course of Pulmonary Remodeling Depend on the Etiology of Lung Injury in Mice

Tatiana Maron-Gutierrez et al.

CRITICAL CARE MEDICINE (2013)

Add to Collection

Article Biochemistry & Molecular Biology

Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury

Mohammad Naimul Islam et al.

NATURE MEDICINE (2012)

Add to Collection

Article Cell & Tissue Engineering

Mesenchymal Stem Cells

Dah-Ching Ding et al.

CELL TRANSPLANTATION (2011)

Add to Collection

Article Cell & Tissue Engineering

Human Mesenchymal Stem Cells Inhibit Vascular Permeability by Modulating Vascular Endothelial Cadherin/beta-Catenin Signaling

Shibani Pati et al.

STEM CELLS AND DEVELOPMENT (2011)

Add to Collection

Article Cell & Tissue Engineering

Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL-37

Anna Krasnodembskaya et al.

STEM CELLS (2010)

Add to Collection

Article Multidisciplinary Sciences

Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung

Jae W. Lee et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

Add to Collection

Review Immunology

Mesenchymal stem cells in health and disease

Antonio Uccelli et al.

NATURE REVIEWS IMMUNOLOGY (2008)

Add to Collection

Review Cell & Tissue Engineering

Isolation of primary and immortalized CD34(-) hematopoietic and mesenchymal stem cells from various sources

R Huss

STEM CELLS (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.